Sesen Bio

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Sesen Bio and buy or sell other stocks, ETFs, and their options commission-free!

About SESN

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. 

CEO
Craig R. Jalbert
CEOCraig R. Jalbert
Employees
46
Employees46
Headquarters
Philadelphia, Pennsylvania
HeadquartersPhiladelphia, Pennsylvania
Founded
2016
Founded2016
Employees
46
Employees46

SESN Key Statistics

Market cap
26.28M
Market cap26.28M
Price-Earnings ratio
0.23
Price-Earnings ratio0.23
Dividend yield
Dividend yield
Average volume
46.86K
Average volume46.86K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$1.27
52 Week high$1.27
52 Week low
$0.0261
52 Week low$0.0261

Stock Snapshot

The current Sesen Bio(SESN) stock price is $0.63, with a market capitalization of 26.28M. The stock trades at a price-to-earnings (P/E) ratio of 0.23.

Sesen Bio(SESN) stock opened on 2026-03-10 at —. The price climbed to — and dipped to —.

Sesen Bio(SESN) shares are trading with a volume of 0, against a daily average of 46.86K.

In the last year, Sesen Bio(SESN) shares hit a 52-week high of $1.27 and a 52-week low of $0.03.

In the last year, Sesen Bio(SESN) shares hit a 52-week high of $1.27 and a 52-week low of $0.03.

People also own

Based on the portfolios of people who own SESN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.